Zhejiang Starry Pharm Co Ltd (603520) - Total Liabilities
Based on the latest financial reports, Zhejiang Starry Pharm Co Ltd (603520) has total liabilities worth CN¥3.69 Billion CNY (≈ $540.43 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Zhejiang Starry Pharm Co Ltd to track the company's year-over-year net asset growth rate.
Zhejiang Starry Pharm Co Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Zhejiang Starry Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Zhejiang Starry Pharm Co Ltd (603520) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Zhejiang Starry Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Starry Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Northfield Bancorp Inc
NASDAQ:NFBK
|
USA | $5.06 Billion |
|
JiangSu JiangHuai Engine Co Ltd
SHE:000816
|
China | CN¥949.07 Million |
|
Vibhavadi Medical Center Public Company Limited
BK:VIBHA
|
Thailand | ฿11.86 Billion |
|
Zhejiang Xiantong Rubber&Plastic Co Ltd
SHG:603239
|
China | CN¥400.42 Million |
|
Harbin Medisan Pharmaceutical Co Ltd
SHE:002900
|
China | CN¥1.70 Billion |
|
MTY Food Group Inc
TO:MTY
|
Canada | CA$1.67 Billion |
|
Indointernet Tbk PT
JK:EDGE
|
Indonesia | Rp2.14 Trillion |
|
MERSEN UNSP.ADR 1/5 EO 2
F:CBE0
|
Germany | €1.01 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Zhejiang Starry Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Zhejiang Starry Pharm Co Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Starry Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Starry Pharm Co Ltd (2011–2025)
The table below shows the annual total liabilities of Zhejiang Starry Pharm Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.59 Billion ≈ $525.48 Million |
+5.27% |
| 2024-12-31 | CN¥3.41 Billion ≈ $499.16 Million |
-9.22% |
| 2023-12-31 | CN¥3.76 Billion ≈ $549.84 Million |
+6.42% |
| 2022-12-31 | CN¥3.53 Billion ≈ $516.69 Million |
+31.71% |
| 2021-12-31 | CN¥2.68 Billion ≈ $392.29 Million |
+5.48% |
| 2020-12-31 | CN¥2.54 Billion ≈ $371.92 Million |
+3.48% |
| 2019-12-31 | CN¥2.46 Billion ≈ $359.41 Million |
+14.57% |
| 2018-12-31 | CN¥2.14 Billion ≈ $313.71 Million |
+87.90% |
| 2017-12-31 | CN¥1.14 Billion ≈ $166.95 Million |
+6.98% |
| 2016-12-31 | CN¥1.07 Billion ≈ $156.06 Million |
+4.50% |
| 2015-12-31 | CN¥1.02 Billion ≈ $149.35 Million |
+42.08% |
| 2014-12-31 | CN¥718.34 Million ≈ $105.12 Million |
+15.34% |
| 2013-12-31 | CN¥622.78 Million ≈ $91.13 Million |
+27.47% |
| 2012-12-31 | CN¥488.57 Million ≈ $71.49 Million |
+15.70% |
| 2011-12-31 | CN¥422.27 Million ≈ $61.79 Million |
-- |
About Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more